HK1090093A1 - Method of selecting patients suitable for wt1 vaccine - Google Patents

Method of selecting patients suitable for wt1 vaccine

Info

Publication number
HK1090093A1
HK1090093A1 HK06110635.4A HK06110635A HK1090093A1 HK 1090093 A1 HK1090093 A1 HK 1090093A1 HK 06110635 A HK06110635 A HK 06110635A HK 1090093 A1 HK1090093 A1 HK 1090093A1
Authority
HK
Hong Kong
Prior art keywords
vaccine
selecting patients
biological sample
precursor cells
highly responsive
Prior art date
Application number
HK06110635.4A
Other languages
English (en)
Inventor
Haruo Sugiyama
Original Assignee
Int Inst Cancer Immunology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Int Inst Cancer Immunology Inc filed Critical Int Inst Cancer Immunology Inc
Publication of HK1090093A1 publication Critical patent/HK1090093A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047Cells of the immune system
    • G01N33/505Cells of the immune system involving T-cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Physiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
HK06110635.4A 2003-06-27 2006-09-22 Method of selecting patients suitable for wt1 vaccine HK1090093A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003184436 2003-06-27
JP2004070497 2004-03-12
PCT/JP2004/009378 WO2005001117A1 (ja) 2003-06-27 2004-06-25 Wt1ワクチン適応患者の選択方法

Publications (1)

Publication Number Publication Date
HK1090093A1 true HK1090093A1 (en) 2006-12-15

Family

ID=33554467

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06110635.4A HK1090093A1 (en) 2003-06-27 2006-09-22 Method of selecting patients suitable for wt1 vaccine

Country Status (10)

Country Link
US (1) US10500257B2 (xx)
EP (3) EP1640458B1 (xx)
JP (1) JP4566912B2 (xx)
KR (2) KR101292971B1 (xx)
CN (1) CN1842603B (xx)
AT (1) ATE538809T1 (xx)
CA (2) CA2893995A1 (xx)
ES (3) ES2478446T3 (xx)
HK (1) HK1090093A1 (xx)
WO (1) WO2005001117A1 (xx)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1178956C (zh) * 1998-07-31 2004-12-08 杉山治夫 基于癌抑制基因wt1的产物的癌抗原
KR100863853B1 (ko) 2001-03-22 2008-10-15 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 더블유티1 개변 펩티드
AU2003262094A1 (en) * 2002-09-12 2004-04-30 Haruo Sugiyama Cancer antigen peptide preparation
JP4566912B2 (ja) 2003-06-27 2010-10-20 株式会社癌免疫研究所 Wt1ワクチン適応患者の選択方法
EP1696027A4 (en) 2003-11-05 2008-05-14 Int Inst Cancer Immunology Inc ANTIGEN PEPTIDE BINDING TO ORIGINAL HLA-DR WT1
DK2186896T3 (en) * 2004-03-31 2015-12-21 Int Inst Cancer Immunology Inc Cancer antigen peptides derived from WT1
JP2008528643A (ja) * 2005-02-04 2008-07-31 スルバック アーぺーエス サバイビンペプチドワクチン
WO2007047764A2 (en) 2005-10-17 2007-04-26 Sloan Kettering Institute For Cancer Research Wt1 hla class ii-binding peptides and compositions and methods comprising same
ES2352855T3 (es) 2005-11-30 2011-02-23 International Institute Of Cancer Immunology, Inc. Nuevos compuestos peptídicos del tumor de wilms.
US9265816B2 (en) 2006-04-10 2016-02-23 Sloan Kettering Institute For Cancer Research Immunogenic WT-1 peptides and methods of use thereof
EP2390361A1 (en) * 2006-06-02 2011-11-30 GlaxoSmithKline Biologicals SA Method for identifying whether a patient will be responder or not to immunotherapy based on the differential expression of the IL7R gene
RU2009135802A (ru) 2007-02-27 2011-04-10 Интернешнл Инститьют Оф Кэнсер Иммунолоджи, Инк. (Jp) Способ активации хелперных т-клеток и композиция для применения в данном способе
MX343633B (es) * 2007-03-05 2016-11-11 Int Inst Cancer Immunology Inc Gen receptor de celulas t especificas de antigeno cancerigeno, peptido codificado por el gen, y uso de los mismos.
CN101888852B (zh) * 2007-12-05 2017-02-08 株式会社癌免疫研究所 癌症疫苗组合物
US10654892B2 (en) 2010-10-05 2020-05-19 International Institute Of Cancer Immunology, Inc. Method for activating helper T cell
WO2013002086A1 (ja) 2011-06-28 2013-01-03 株式会社癌免疫研究所 ペプチド癌抗原特異的t細胞のレセプター遺伝子
EP2561759A1 (en) 2011-08-26 2013-02-27 Bayer Cropscience AG Fluoroalkyl-substituted 2-amidobenzimidazoles and their effect on plant growth
BR112014006217B1 (pt) 2011-09-16 2019-01-15 Bayer Intellectual Property Gmbh utilização de acilsulfonamidas para melhorar o rendimento de plantas,método para induzir respostas de regulação de crescimento em plantas úteis ou plantas de cultura e composição.
UA113967C2 (xx) 2011-09-16 2017-04-10 Застосування 5-феніл- або 5-бензил-2-ізоксазолін-3-карбоксилатів для покращення урожайності рослин
BR112014005990B1 (pt) 2011-09-16 2019-12-31 Bayer Ip Gmbh método para induzir uma resposta específica de regulação do crescimento de plantas
JP6282598B2 (ja) 2012-01-13 2018-02-21 メモリアル スローン ケタリング キャンサー センター 免疫原性wt1ペプチド及びその使用方法
KR20150092122A (ko) 2012-10-23 2015-08-12 프로비던스 헬스 앤드 서비시즈, 오레곤 질환 치료용 동종 자가포식소체-강화된 조성물
TWI646970B (zh) 2012-12-17 2019-01-11 大塚製藥股份有限公司 活化輔助t細胞的方法
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
CA2898099A1 (en) * 2013-01-15 2014-07-24 David A. Scheinberg Immunogenic wt-1 peptides and methods of use thereof
WO2014135481A1 (en) 2013-03-05 2014-09-12 Bayer Cropscience Ag Use of quinoline derivatives for improving plant yield
RS59150B1 (sr) 2013-03-05 2019-09-30 Bayer Cropscience Ag Upotreba n-(2-metoksibenzoil)-4-[metilaminokarbonil)amino]benzensulfonamida u kombinaciji sa insekticidom ili fungicidom za poboljšanje prinosa biljaka
ES2713648T3 (es) * 2013-03-28 2019-05-23 Ct Hospitalier Universitaire Montpellier Método para determinar la radiosensibilidad
JP6634287B2 (ja) 2013-05-13 2020-01-22 株式会社癌免疫研究所 免疫療法の臨床効果の予測法
HRP20220994T1 (hr) 2015-11-20 2022-11-11 Memorial Sloan Kettering Cancer Center Sastav za liječenje raka
EP3318135A1 (en) 2016-11-03 2018-05-09 Perfetti Van Melle S.p.A. Effervescent candy material, a process for its preparation and products made therefrom
US20230183316A1 (en) * 2020-05-12 2023-06-15 Sumitomo Pharma Co., Ltd. Pharmaceutical composition for treating cancer

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4923799A (en) 1984-02-06 1990-05-08 The Ontario Cancer Institute T cell specific cDNA clone
US6582908B2 (en) 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
JPH07504399A (ja) 1991-08-28 1995-05-18 ザ・ウィスター・インスティチュート T細胞リセプターに基づいた慢性間接リウマチの治療法
US5364787A (en) 1992-03-23 1994-11-15 Idaho Research Foundation Genes and enzymes involved in the microbial degradation of pentachlorophenol
ES2242221T3 (es) * 1996-04-16 2005-11-01 Kishimoto, Tadamitsu Procedimiento para la deteccion de celulas de cancer solido y de heterotipia histologica y procedimiento para el examen de tejidos destinados a trasplantes de medula osea y al trasplante de celulas madre sanguineas perifericas.
GB9710820D0 (en) 1997-05-27 1997-07-23 Univ Dundee Immunological method
US6013444A (en) 1997-09-18 2000-01-11 Oligotrail, Llc DNA bracketing locus compatible standards for electrophoresis
AU5528198A (en) 1997-12-03 1999-06-16 Immune Response Corporation, The Vaccination and methods against multiple sclerosis using specific tcr vbeta peptides
SK17332000A3 (sk) 1998-05-19 2001-06-11 Avidex Limited Preskladaný rekombinantný t bunkový receptor-tcr, sekvencie nukleových kyselín, ktoré kódujú rekombinantné tcr reťazce rekombinantného tcr, a spôsob jeho výroby
CN1178956C (zh) 1998-07-31 2004-12-08 杉山治夫 基于癌抑制基因wt1的产物的癌抗原
DE69938970D1 (de) 1998-09-30 2008-08-07 Corixa Corp Zusammensetzungen und verfahren für wt1-spezifische immunotherapie
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030072767A1 (en) * 1998-09-30 2003-04-17 Alexander Gaiger Compositions and methods for WT1 specific immunotherapy
GB9823897D0 (en) 1998-11-02 1998-12-30 Imp College Innovations Ltd Immunotherapeutic methods and molecules
AU774952B2 (en) 1999-02-23 2004-07-15 Baylor College Of Medicine T cell receptor Vbeta-Dbeta-Jbeta sequence and methods for its detection
AU2001265346A1 (en) * 2000-06-02 2001-12-17 Memorial Sloan-Kettering Cancer Center Artificial antigen presenting cells and methods of use thereof
AU2002222610A1 (en) 2000-12-13 2002-06-24 Sumitomo Pharmaceuticals Company, Limited Transgenic animal expressing hla-a24 and utilization thereof
KR100863853B1 (ko) 2001-03-22 2008-10-15 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 더블유티1 개변 펩티드
WO2003002142A1 (en) * 2001-06-29 2003-01-09 Chugai Seiyaku Kabushiki Kaisha Cancer vaccine containing cancer antigen based on tumor suppressor gene wt1 product and cationic liposomes
US20060035291A1 (en) 2001-09-18 2006-02-16 Kyogo Itoh Method of detecting cellular immunity and application thereof to drugs
JPWO2003028758A1 (ja) 2001-09-28 2005-01-13 治夫 杉山 抗原特異的t細胞の誘導方法
EP1447091A4 (en) 2001-09-28 2008-02-13 Institute Of Can International NEW METHOD FOR INDUCTION OF ANTIGEN SPECIFIC T CELLS
AU2003207528A1 (en) 2002-01-09 2003-07-30 Maxx Genetech Co. Ltd Method of detecting t-cell proliferation for diagnosis of diseases by gene array
AU2003242305A1 (en) * 2002-06-12 2003-12-31 Chugai Seiyaku Kabushiki Kaisha Hla-a24-restricted cancer antigen peptide
AU2003262094A1 (en) 2002-09-12 2004-04-30 Haruo Sugiyama Cancer antigen peptide preparation
WO2004063706A2 (en) 2003-01-08 2004-07-29 Maxx Genetech Co., Ltd. Method of detecting over-expression of t-cell receptor genes by real-time pcr
JP4566912B2 (ja) 2003-06-27 2010-10-20 株式会社癌免疫研究所 Wt1ワクチン適応患者の選択方法
EP1696027A4 (en) 2003-11-05 2008-05-14 Int Inst Cancer Immunology Inc ANTIGEN PEPTIDE BINDING TO ORIGINAL HLA-DR WT1
US20070238099A1 (en) 2003-12-08 2007-10-11 Cohen Irun R Antigen Receptor Variable Region Typing
US7576183B2 (en) 2003-12-24 2009-08-18 Los Alamos National Security, Llc Structure-based receptor MIMICS targeted against bacterial superantigen toxins
DK2186896T3 (en) 2004-03-31 2015-12-21 Int Inst Cancer Immunology Inc Cancer antigen peptides derived from WT1
GB0411771D0 (en) 2004-05-26 2004-06-30 Avidex Ltd Nucleoproteins displaying native T cell receptor libraries
GB0427585D0 (en) 2004-12-16 2005-01-19 Avidex Ltd Assay
WO2008026927A2 (en) 2006-08-30 2008-03-06 Academisch Medisch Centrum Process for displaying t- and b-cell receptor repertoires
MX343633B (es) 2007-03-05 2016-11-11 Int Inst Cancer Immunology Inc Gen receptor de celulas t especificas de antigeno cancerigeno, peptido codificado por el gen, y uso de los mismos.
JP2009278927A (ja) 2008-05-23 2009-12-03 Tohoku Univ T細胞受容体を模倣する抗体断片及びその製造方法
WO2013002086A1 (ja) 2011-06-28 2013-01-03 株式会社癌免疫研究所 ペプチド癌抗原特異的t細胞のレセプター遺伝子

Also Published As

Publication number Publication date
CN1842603B (zh) 2013-09-11
EP2343083A3 (en) 2011-08-03
EP2338509A3 (en) 2011-11-30
CA2530184C (en) 2015-10-06
CA2530184A1 (en) 2005-01-06
JP4566912B2 (ja) 2010-10-20
WO2005001117A1 (ja) 2005-01-06
KR20110049877A (ko) 2011-05-12
EP2338509A2 (en) 2011-06-29
KR20060069363A (ko) 2006-06-21
EP2343083A2 (en) 2011-07-13
EP1640458A1 (en) 2006-03-29
KR101292971B1 (ko) 2013-08-12
ES2478446T3 (es) 2014-07-22
ATE538809T1 (de) 2012-01-15
EP1640458B1 (en) 2011-12-28
EP1640458A4 (en) 2008-05-21
ES2378156T3 (es) 2012-04-09
US20070128207A1 (en) 2007-06-07
ES2443582T3 (es) 2014-02-19
EP2343083B1 (en) 2014-01-15
KR101431312B1 (ko) 2014-08-20
JPWO2005001117A1 (ja) 2006-08-10
EP2338509B1 (en) 2014-06-18
CN1842603A (zh) 2006-10-04
CA2893995A1 (en) 2005-01-06
US10500257B2 (en) 2019-12-10

Similar Documents

Publication Publication Date Title
HK1090093A1 (en) Method of selecting patients suitable for wt1 vaccine
RU2007141067A (ru) Терапия с помощью антител к egfr, основанная на повышенном числе копий гена egfr в опухолевых тканях
AU2001253079A1 (en) Methods, compositions and kits for the detection and monitoring of breast cancer
EP1561106A4 (en) DIAGNOSTIC ASSAY FOR DETERMINING A CELL-MEDIATED IMMUNE RESPONSE
TW200626899A (en) Frizzled proteins and detection and treatment of cancer
TW200626900A (en) Wnt proteins and detection and treatment of cancer
WO2004091384A3 (en) Erbb surface receptor complexes as biomarkers
SG10201804260QA (en) Diagnostic assays and kits for detection of folate receptor 1
WO2008141282A3 (en) Materials and methods for foxp3 tumor suppression
JP2014512006A5 (xx)
WO2006034328A3 (en) Wnt proteins and detection and treatment of cancer
WO2003014395A1 (fr) Methode d'examen de l'asthme bronchique
Chonanant et al. Characterisation of chondrogenic differentiation of human mesenchymal stem cells using synchrotron FTIR microspectroscopy
WO2003016464A3 (en) Cancer specific oligosaccharide sequences and use thereof
WO2012044696A3 (en) Prediction of clinical outcome in hematological malignancies using a self-renewal expression signature
ATE302410T1 (de) Verfahren und vorrichtung zur messung von blutgasparametern
WO2006023563A3 (en) A diagnostic imaging device for the analysis of circulating rare cells
ATE514951T1 (de) Verfahren zur prüfung eines mehrkanaligen elements zur blutanalyse
MXPA05014220A (es) Genes regulados en cancer ovarico como objetivos de pronostico y terapeuticos.
WO2007071829A3 (en) Methods and means related to diseases
BRPI0315735B8 (pt) método para o ensaio de ngf a diagnose in vitro de câncer de mama e uso terapêutico
EP1600513A4 (en) METHOD FOR STUDYING A CELL
EP2539709A4 (en) ALTERNATIVES SPECIFIC TO ALZHEIMER'S DISEASE PROTEIN KINASE C EPSILON LEVELS (PKC-EPSILON)
Hu et al. Detection of hypoxic fractions in murine tumors by comet assay: comparison with other techniques
WO2012032511A3 (en) Kit for monitoring, detecting and staging gvhd

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20200625